Supporting data for “Characterization of Immune-Modulating Metabolites as Biomarkers in Non-Small Cell Lung Cancer: Role in Brain Metastasis and Treatment Response Prediction”

Non-Small Cell Lung cancer (NSCLC) threatened human health worldwide, which was mainly caused by brain metastasis (Bramet) and dismal treatment responses. The immune modulating metabolites such as indoleamine 2,3-dioxygenase (IDO), which can converse tryptophan to kynurenine, were associated with distant metastasis and overall survival (OS) in NSCLC by regulating the immune system. Specifically, this study aimed to examine whether the IDO metabolites are correlated with immune status and subsequent OS in NSCLC patients with Bramet by FACS and HPLC and identify other potential immune-modulating metabolites as predictive biomarkers in treatment responses which may help personalized radiotherapy by metabolomics profiling.  These immune-modulating metabolites may serve as a basis for further application in cancer diagnosis and personalized cancer therapies.